NHS Cancer Blood Tests Trial for Patients Over 45

Thousands of Brits aged 45 and over who visit their general practitioners with vague symptoms will receive blood tests to detect cancer as part of a new NHS trial. The initiative, named STRIDE-RCT, involves more than 20,000 NHS patients from 200 GP surgeries across England. Scientists hope the study will catch cancer cases in their earliest stages while reducing unnecessary hospital referrals for invasive tests.

Abdominal cancers often present with signs that are difficult to diagnose promptly, as persistent bloating or stomach discomfort can easily be mistaken for minor health issues. Around 71,000 people receive a diagnosis of bowel, stomach, liver, pancreatic, or ovarian cancer in England each year. These specific conditions cause nearly 35,000 deaths annually, according to figures from the National Institute for Health and Care Research.

Who Is Eligible for the STRIDE-RCT Cancer Blood Test Trial?

The new screening evaluation targets patients aged 45 and older who consult their GP regarding abdominal symptoms. Participants will have one or two tubes of blood drawn at their surgery during routine appointments. A positive result provides doctors with guidance on whether an urgent hospital referral is necessary, though the procedure does not serve as a standalone cancer diagnosis.

The trial focuses on catching multiple forms of abdominal cancer earlier than standard diagnostic pathways allow. Work so far suggests the blood evaluations could identify signs of bowel, ovarian, lung, pancreatic, liver, bile duct, and stomach cancer. The National Institute for Health and Care Research backs the project to determine whether health authorities should roll out the technology nationwide across the NHS.

How the Three New Blood Tests Work

The trial uses three distinct blood tests known as the Enlighten test, the PinPoint test, and the Halo test, with the possibility that further tests will be added later. Once medical staff draw the blood sample, laboratories apply artificial intelligence, tumour DNA detection, and blood protein measurements to search for signs of multiple cancers within a single sample.

Laboratories return the results to the patient's GP using a red, amber, and green system to recommend the next course of action. A green result suggests low risk and acts as a rule-out, amber indicates average risk requiring standard assessment, and red signifies high risk which should be prioritized for urgent investigation.

Why Vague Symptoms Delay Cancer Diagnoses

Detecting abdominal cancers early remains a major challenge for medical professionals because the initial warning signs are frequently vague and non-specific. Patients often experience persistent bloating or abdominal discomfort without realizing these are indicators of serious illness. Because these symptoms mirror benign conditions, many people receive a formal diagnosis too late for optimal treatment outcomes.

Doctors have long needed better tools to help them navigate diagnostic uncertainty and identify which patients require further testing. Health secretary Yvette Cooper stated that the earlier cancers are diagnosed, the more chance they can be successfully treated and lives can be saved. The STRIDE-RCT study aims to provide the necessary evidence to bridge this clinical gap.

Expert Opinions on the National Health Service Trial

Professor Peter Johnson, NHS national clinical director for cancer, noted that the health service stands at the start of a revolution in cancer diagnosis. He explained that the trial will help authorities find out whether blood tests can help GPs direct the right patients to the right tests sooner. Professor Johnson expressed gratitude to everyone taking part in the research initiative.

Michelle Mitchell, chief executive of Cancer Research UK, also welcomed the trial and stated its findings will be valuable in guiding further research. She noted that the evaluation serves as an important step toward addressing the need for better primary care diagnostic tools. The findings from the 20,000 participants will dictate whether the program expands to every region of the country.